Ardelyx Targets $500M Revenue This Year, Profitability by 2027
Ardelyx Inc ARDX
$3.42
▼ -0.87%
($-0.03)
Open
$3.47
Prev Close
$3.45
Day Range
$3.40 – $3.49
52W Range
$3.33 – $8.40
Market Cap
$852.22M
Beta
0.72
EPS (TTM)
$-0.23
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-06-19 |
| Shares Out. | 247,030,000 |
| Website | ardelyx.com/ ↗ |
| Phone | 13026974590 |
| Employees | 489 |
| Revenue | $120.9M |
| Gross Profit | $115.1M |
| Net Income | -$16.7M |
| Free Cash Flow | -$17.9M |
| Total Assets | $575.9M |
| Total Liabilities | $426.9M |
| Equity | $149.0M |
About Ardelyx Inc
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Ardelyx Inc is a publicly traded company under the ticker symbol ARDX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-09-01)